Literature DB >> 10363157

[Control of tumor-related angiogenesis].

T Oikawa1.   

Abstract

Tumor-related angiogenes is expected to become an important target for improving treatment of cancer, because it plays key roles in tumor growth, invasion and metastasis. We considered that the successful development of such angiostatic treatment depended entirely upon the development of useful anti-angiogenic agents, and attempted to find novel angiogenesis inhibitors by using three in vivo assays, based on an idea of ours. As a result we have demonstrated that different types of agents with low molecular weight including microbial metabolites, cell differentiation modulators like retinoids and steroids, exhibit anti-angiogenic activity, anti-metastatic activity and/or antitumor activity. Taken these findings, an ideal anti-angiogenic agent is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10363157

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  1 in total

1.  A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.

Authors:  Kimberly B Higginbotham; Richard Lozano; Thomas Brown; Yehuda Z Patt; Takashi Arima; James L Abbruzzese; Melanie B Thomas
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-27       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.